足月引产妇女阴道与颊部米索前列醇促宫颈成熟比较(IMPROVE试验):三盲随机对照试验
IMPROVE三盲安慰剂对照随机非劣效性试验纳入足月初产、Bishop评分≤6的引产妇女,比较阴道与颊部米索前列醇促宫颈成熟,计划样本300例,实际分析300例(阴道组152例、颊部组148例)。未能证明颊部方案非劣效;阴道组至阴道分娩时间更短、24小时内阴道分娩率更高、因胎儿窘迫紧急剖宫产率更低。
要点
- 足月引产Bishop评分≤6者,阴道米索前列醇组至阴道分娩中位时间20.1小时,颊部组28.1小时(P=0.006)。
- 因胎儿状况不佳行剖宫产率阴道组3.3%,颊部组9.5%(P=0.033)。
- 24小时内阴道分娩率阴道组58.6%,颊部组39.2%(P=0.001)。
核心结论
- 未能证明颊部米索前列醇相对于阴道米索前列醇的非劣效性;阴道米索前列醇可能优于颊部米索前列醇用于足月促宫颈成熟,因其阴道分娩率更高、阴道分娩更快、因胎儿问题剖宫产更少。
研究设计与样本
- IMPROVE试验为经机构审查委员会批准的三盲、安慰剂对照、随机非劣效性试验,纳入足月引产且Bishop评分≤6的妇女。
- 入组妇女首剂接受25 mcg米索前列醇,后续剂量50 mcg,按随机分配的途径(阴道或颊部)给药,并在另一途径给予匹配的安慰剂片。
- 计划样本量300例以检验非劣效性假设;实际入组319例,300例纳入分析,阴道米索前列醇组152例,颊部组148例。
主要发现
- 两组基线特征相似。
- 至阴道分娩时间阴道米索前列醇组中位20.1小时(95%CI 18.2–22.8),颊部组28.1小时(95%CI 24.1–31.4),log-rank检验P=0.006,非劣效性P=0.663。
- 因胎儿状况不佳行剖宫产率阴道米索前列醇组3.3%,颊部组9.5%(P=0.033)。
- 24小时内阴道分娩率阴道组58.6%,颊部组39.2%(P=0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cervical ripening is commonly needed for labor induction. Finding an optimal route of misoprostol dosing for efficacy, safety, and patient satisfaction is important and not well studied for the buccal route. OBJECTIVE: To compare the efficacy and safety of vaginal and buccal misoprostol for women undergoing labor induction at term. STUDY DESIGN: The IMPROVE trial was an institutional review board-approved, triple-masked, placebo-controlled randomized noninferiority trial for women undergoing labor induction at term with a Bishop score ≤6. Enrolled women received 25 mcg (first dose), then 50 mcg (subsequent doses) of misoprostol by assigned route (vaginal or buccal) and a matching placebo tablet by the opposite route. The primary outcomes were time to delivery and the rate of cesarean delivery performed urgently for fetal nonreassurance. A sample size of 300 was planned to test the noninferiority hypothesis. RESULTS: The trial enrolled 319 women, with 300 available for analysis, 152 in the vaginal misoprostol group and 148 in the buccal. Groups had similar baseline characteristics. We were unable to demonstrate noninferiority. The time to vaginal delivery was lower for the vaginal misoprostol group (median [95% confidence interval] in hours: vaginal: 20.1 [18.2, 22.8] vs buccal: 28.1 [24.1, 31.4], log-rank test P = .006, Pnoninferiority = .663). The rate of cesarean deliveries for nonreassuring fetal status was 3.3% for the vaginal misoprostol group and 9.5% for the buccal misoprostol group (P = .033). The rate of vaginal delivery in <24 hours was higher in the vaginal group (58.6% vs 39.2%, P = .001). CONCLUSION: We were unable to demonstrate noninferiority. In leading to a higher rate of vaginal deliveries, more rapid vaginal delivery, and fewer cesareans for fetal issues, vaginal misoprostol may be superior to buccal misoprostol for cervical ripening at term.
引用
- Haas DM, Daggy J, Flannery KM, et al. A comparison of vaginal versus buccal misoprostol for cervical ripening in women for labor induction at term (the IMPROVE trial): a triple-masked randomized controlled trial. Am J Obstet Gynecol. 2019. PMID: 31075246. doi:10.1016/j.ajog.2019.04.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。